Company
BrainChild Bio
Advancing CAR T cell therapies to combat incurable CNS tumors
Also known as BRAINCHILD BIO, INC.
- Status
- Operatingas of 2026-09-19Source (opens in a new tab)
- Business model
- B2B
- Headquarters
- Seattle, WA, United States
- Legal name
- BRAINCHILD BIO, INC.
- brainchildbio.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
BrainChild Bio is a clinical-stage biotechnology company leading the field in the development of CAR T cell therapies for tumors in the central nervous system (CNS). We are kids-first, prioritizing pediatric brain tumors, with a pipeline that extends our technology platform to adult indications, including glioblastoma and brain metastases.
Funding snapshot
- Total raised
- $116MSum of rounds, as of 2026-09-19Source (opens in a new tab)
- Latest round
- Series A, $116M2026-09-08
Funding rounds
- Series A
- $116M2026-09-08, Company stated
Products
- Other
- BCB-276
Loading relationship preview